Document:

Exhibit
10.7

 

__________,
2022

 

EF
Hutton,

division
of Benchmark Investments, LLC

as
Representative of the several Underwriters named on Schedule 1 attached hereto

590
Madison Avenue, 39th Floor

New
York, New York 10022

 

Re:
TC BioPharm (Holdings) Limited – Public Offering

 

Ladies
and Gentlemen:

 

The
undersigned holder convertible loan notes issued by the Company (defined below) with the right to obtain ordinary shares, par value £0.01
per share (“Ordinary Shares”), or rights to acquire Ordinary Shares through American Depositary Shares and warrants
to purchase Ordinary Shares or American Depositary Shares (“Investor Warrants”) of TC BioPharm (Holdings) Limited, a private
company limited by shares organized under the law of Scotland, United Kingdom (the “Company”), understands that you
are the representative (the “Representative”) of the several underwriters, if any (collectively, the “Underwriters”),
named or to be named in the final form of Schedule I to the underwriting agreement (the “Underwriting Agreement”)
to be entered into by the several Underwriters and the Company, providing for the public offering of Ordinary Shares through American
depositary Shares and Investor Warrants (the “Public Offering”) registered with the U.S. Securities and Exchange Commission
(the “SEC”) under the Securities Act of 1933, as amended. Capitalized terms used herein and not otherwise defined
shall have the meanings set forth in the Underwriting Agreement.

 

For
purposes of this Agreement, references to (a) “Company” shall include TC BioPharm (Holdings) plc, a public limited company
organized or to be organised under the law of Scotland, United Kingdom that will succeed to the interests of the Company pursuant to
a reorganization prior to the closing of the Public Offering and that will be the issuer of the Ordinary Shares and Investor Warrants
in the Public Offering, (b) “Ordinary Shares” shall include the ordinary shares of TC BioPharm (Holdings) plc and American
Depositary Shares representing the Ordinary Shares, and (c) “Investor Warrants” shall include the warrant securities, the
underlying Ordinary Shares and the American Depositary Shares into which the underlying Ordinary Shares may be dematerialized.

 

In
consideration of the Underwriters’ agreement to enter into the Underwriting Agreement and to proceed with the Public Offering,
and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the undersigned hereby agrees,
for the benefit of the Company, the Representative and the other Underwriters that, without the prior written consent of the Representative,
the undersigned will not, during the period specified in the following paragraph (the “Lock-Up Period”), directly
or indirectly, unless otherwise provided herein, (a) offer, sell, agree to offer or sell, solicit offers to purchase, grant any call
option or purchase any put option with respect to, pledge, encumber, assign, borrow or otherwise dispose of (each a “Transfer”)
any Relevant Security (as defined below) or otherwise publicly disclose the intention to do so, or (b) establish or increase any “put
equivalent position” or liquidate or decrease any “call equivalent position” with respect to any Relevant Security
(in each case within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),
and the rules and regulations thereunder) with respect to any Relevant Security or otherwise enter into any swap, derivative or other
transaction or arrangement that Transfers to another, in whole or in part, any economic consequence of ownership of a Relevant Security,
whether or not such transaction is to be settled by the delivery of Relevant Securities, other securities, cash or other consideration,
or otherwise publicly disclose the intention to do so. As used herein, the term “Relevant Security” means Ordinary
Shares, Investor Warrants, any warrant to purchase Ordinary Shares or any other security of the Company or any other entity that is convertible
into, or exercisable or exchangeable for, Ordinary Shares or any other equity or equity linked security of the Company, including any
American Depositary Shares representing the foregoing, in each case owned beneficially or otherwise by the undersigned on the date of
closing of the Public Offering or acquired by the undersigned during the Lock-Up Period.

 

    	 

     

    

 

The
restrictions in the foregoing paragraph shall not apply to (a) any exercise (including a cashless exercise or broker-assisted exercise
and payment of tax obligations) of options or warrants to purchase Shares; provided that any Shares received upon such exercise, conversion
or exchange will be subject to the Lock-Up Period, (b) any establishment of a trading plan pursuant to Rule 10b5-1 under the Exchange
Act for the transfer of Shares (a “Trading Plan”), provided that (i) the Trading Plan shall not provide for or permit
any transfers, sales or other dispositions of Shares during the Lock-Up Period and (ii) the Trading Plan would not require any filing
under Section 16(a) of the Exchange Act and no such filing is voluntarily made, or (c) any transfer of Ordinary Shares acquired in open
market transactions following the closing of the Public Offering, provided the transfer would not require any filing under Section 16(a)
of the Exchange Act and no such filing is voluntarily made. The Lock-Up Period will commence on the date of this Agreement and continue
and include the date that is one-hundred eighty (180) days after the closing of the Public Offering.

 

Notwithstanding
the lock up provisions, the undersigned will be able to sell, during any one week in the Lock-Up Period, only those Ordinary Shares and/or
Investor Warrants received on exercise of the 90 day option representing up to an aggregate of the American Depositary Shares of the
Company equal to 10% of the average daily trading volume during the immediately preceding calendar week, as defined by Bloomberg LLP.
No shares that may be sold but are not sold may be carried over from one week to the next. In addition, the lock up provisions of this
letter and the 10% weekly leak out provision will terminate prior to the end of the Lock-Up Period as follows, (i) as to 50% of the Relevant
Securities if the average daily closing price, as reported by Bloomberg LLP, at which an American Depositary Shares trades in any consecutive
10 trading days exceeds 200% of the in initial IPO offering price of a American Depositary Share (disregarding any amount attributable
to the Investor Warrant), and (i) as to 100% of the Relevant Securities, if the average daily closing price, as reported by Bloomberg
LLP at which an American Depositary Share trades in any consecutive 14 trading days exceeds 225% of the initial IPO offering price of
a American Depositary Share (disregarding any amount attributable to the Investor Warrant).

 

In
addition, the undersigned further agrees that, except for the registration statement filed or to be filed in connection with the Public
Offering, during the Lock-Up Period the undersigned will not, without the prior written consent of the Representative: (a) file or participate
in the filing with the SEC of any registration statement or circulate or participate in the circulation of any preliminary or final prospectus
or other disclosure document, in each case with respect to any proposed offering or sale of a Relevant Security beneficially owned by
the undersigned, or (b) exercise any rights the undersigned may have to require registration with the SEC of any proposed offering or
sale of a Relevant Security beneficially owned by the undersigned.

 

In
furtherance of the undersigned’s obligations hereunder, the undersigned hereby authorizes the Company during the Lock-Up Period
to cause any transfer agent for the Relevant Securities to decline to transfer, and to note stop transfer restrictions on the stock register
and other records relating to, Relevant Securities for which the undersigned is the record owner and the transfer of which would be a
violation of this Agreement and, in the case of Relevant Securities for which the undersigned is the beneficial but not the record owner,
agrees that during the Lock-Up Period it will use its reasonable best efforts to cause the record owner to authorize the Company to cause
the relevant transfer agent to decline to transfer, and to note stop transfer restrictions on the stock register and other records relating
to, such Relevant Securities to the extent such transfer would be a violation of this Agreement.

 

    	 

     

    

 

Notwithstanding
the foregoing, the undersigned may transfer the undersigned’s Relevant Securities:

 

	 	(i)	as
    a bona fide gift or gifts;
	 	 	 
	 	(ii)	to
    any trust, partnership, limited liability company or other legal entity commonly used for estate planning purposes which is established
    for the direct or indirect benefit of the undersigned or a member or members of the immediate family of the undersigned;
	 	 	 
	 	(iii)	if
    the undersigned is a corporation, partnership, limited liability company, trust or other business entity, (1) to another corporation,
    partnership, limited liability company, trust or other business entity that is a direct or indirect affiliate (as defined in Rule
    405 under the Securities Act of 1933, as amended) of the undersigned, (2) to limited partners, limited liability company members
    or stockholders of the undersigned or holders of similar equity interests in the undersigned, or (3) in connection with a sale, merger
    or transfer of all or substantially all of the assets of the undersigned or any other change of control of the undersigned, not undertaken
    for the purpose of avoiding the restrictions imposed by this Agreement;
	 	 	 
	 	(iv)	if
    the undersigned is a trust, to the beneficiary of such trust;
	 	 	 
	 	(v)	by
    testate or intestate succession;
	 	 	 
	 	(vi)	by
    operation of law, such as pursuant to a qualified domestic order or in connection with a divorce settlement;
	 	 	 
	 	(vii)	pursuant
    to the Underwriting Agreement; or
	 	 	 
	 	(viii)	to
    the Company, it the Company agrees, solely in an amount necessary to satisfy tax obligations (withholding or otherwise) in connection
    with any grant of restricted Ordinary Shares, exercise or vesting of options or warrants to purchase Ordinary Shares, 

 

provided,
however, in the case of clauses (i)-(vi), that (A) such transfer shall not involve a disposition for value, (B) the transferee agrees
in writing with the Underwriters and the Company to be bound by the terms of this Agreement, and (C) such transfer would not require
any filing under Section 16(a) of the Exchange Act and no such filing is voluntarily made.

 

For
purposes of this Agreement, “immediate family” shall mean any relationship by blood, marriage or adoption, not more remote
than first cousin.

 

The
undersigned hereby represents and warrants that (a) the undersigned has full power and authority to enter into this Agreement, (b) this
Agreement has been duly authorized (if the undersigned is not a natural person) or, in the case of a natural person, such person has
the legal capacity to enter into this Agreement, and (c) this Agreement constitutes the legal, valid and binding obligation of the undersigned,
enforceable against the undersigned in accordance with its terms. Upon request, the undersigned will execute any additional documents
necessary in connection with the enforcement hereof. Any obligations of the undersigned shall be binding upon the successors and assigns
of the undersigned from the date of this Agreement.

 

The
undersigned understands that, if the Underwriting Agreement does not become effective, or if the Underwriting Agreement (other than the
provisions thereof which survive termination) shall terminate or be terminated prior to payment for and delivery of the Securities to
be sold thereunder, the undersigned shall be released from all obligations under this Agreement.

 

    	 

     

    

 

The
undersigned, whether or not participating in the Public Offering, understands that the Underwriters are entering into the Underwriting
Agreement and proceeding with the Public Offering in reliance upon this Agreement.

 

This
Agreement shall be governed by and construed in accordance with the law of the State of New York. Delivery of a signed copy of this Agreement
by facsimile or e-mail/.pdf transmission shall be effective as the delivery of the original hereof.

 

	 	Very truly yours, 
	 	 	 
	 	Signature:	 
	 	 	 
	 	Name
    (printed):	 
	 	 	 
	 	Title
    (if applicable):	 
	 	 	 
	 	Entity
    (if applicable):Exhibit
10.10

 

__________,
2022

 

EF
Hutton,

division
of Benchmark Investments, LLC

as
Representative of the several Underwriters named on Schedule 1 attached hereto

590
Madison Avenue, 39th Floor

New
York, New York 10022

 

Re:
TC BioPharm (Holdings) Limited – Public Offering

 

Ladies
and Gentlemen:

 

The
undersigned holder of convertible loan notes issued by the Company (defined below) with the right to obtain ordinary shares, par value
£0.01 per share (“Ordinary Shares”), or rights to acquire Ordinary Shares through American Depositary Shares
and warrants to purchase Ordinary Shares or American Depositary Shares (“Investor Warrants”) of TC BioPharm (Holdings) Limited,
a private company limited by shares organized under the law of Scotland, United Kingdom (the “Company”), understands
that you are the representative (the “Representative”) of the several underwriters, if any (collectively, the “Underwriters”),
named or to be named in the final form of Schedule I to the underwriting agreement (the “Underwriting Agreement”)
to be entered into by the several Underwriters and the Company, providing for the public offering of Ordinary Shares through American
Depositary Shares and Investor Warrants (the “Public Offering”) registered with the U.S. Securities and Exchange Commission
(the “SEC”) under the Securities Act of 1933, as amended. Capitalized terms used herein and not otherwise defined
shall have the meanings set forth in the Underwriting Agreement.

 

For
purposes of this Agreement, references to (a) “Company” shall include TC BioPharm (Holdings) plc, a public limited company
organized or to be organised under the law of Scotland, United Kingdom that will succeed to the interests of the Company pursuant to
a reorganization prior to the closing of the Public Offering and that will be the issuer of the Ordinary Shares and Investor Warrants
in the Public Offering, (b) “Ordinary Shares” shall include the ordinary shares of TC BioPharm (Holdings) plc and American
Depositary Shares representing the Ordinary Shares, and (c) “Investor Warrants” shall include the warrant securities, the
underlying Ordinary Shares and the American Depositary Shares into which the underlying Ordinary Shares may be dematerialized.

 

In
consideration of the Underwriters’ agreement to enter into the Underwriting Agreement and to proceed with the Public Offering,
and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the undersigned hereby agrees,
for the benefit of the Company, the Representative and the other Underwriters that, without the prior written consent of the Representative,
the undersigned will not, during the period specified in the following paragraph (the “Lock-Up Period”), directly
or indirectly, unless otherwise provided herein, (a) offer, sell, agree to offer or sell, solicit offers to purchase, grant any call
option or purchase any put option with respect to, pledge, encumber, assign, borrow or otherwise dispose of (each a “Transfer”)
any Relevant Security (as defined below) or otherwise publicly disclose the intention to do so, or (b) establish or increase any “put
equivalent position” or liquidate or decrease any “call equivalent position” with respect to any Relevant Security
(in each case within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),
and the rules and regulations thereunder) with respect to any Relevant Security or otherwise enter into any swap, derivative or other
transaction or arrangement that Transfers to another, in whole or in part, any economic consequence of ownership of a Relevant Security,
whether or not such transaction is to be settled by the delivery of Relevant Securities, other securities, cash or other consideration,
or otherwise publicly disclose the intention to do so. As used herein, the term “Relevant Security” means Ordinary
Shares, Investor Warrants, any warrant to purchase Ordinary Shares or any other security of the Company or any other entity that is convertible
into, or exercisable or exchangeable for, Ordinary Shares or any other equity or equity linked security of the Company, including any
American Depositary Shares representing the foregoing, in each case owned beneficially or otherwise by the undersigned on the date of
closing of the Public Offering or acquired by the undersigned during the Lock-Up Period.

 

    	 

     

    

 

The
restrictions in the foregoing paragraph shall not apply to (a) any exercise (including a cashless exercise or broker-assisted exercise
and payment of tax obligations) of options or warrants to purchase Shares; provided that any Shares received upon such exercise, conversion
or exchange will be subject to the Lock-Up Period, (b) any establishment of a trading plan pursuant to Rule 10b5-1 under the Exchange
Act for the transfer of Shares (a “Trading Plan”), provided that (i) the Trading Plan shall not provide for or permit
any transfers, sales or other dispositions of Shares during the Lock-Up Period and (ii) the Trading Plan would not require any filing
under Section 16(a) of the Exchange Act and no such filing is voluntarily made, or (c) any transfer of Ordinary Shares acquired in open
market transactions following the closing of the Public Offering, provided the transfer would not require any filing under Section 16(a)
of the Exchange Act and no such filing is voluntarily made. The Lock-Up Period will commence on the date of this Agreement and continue
and include the date that is one-hundred eighty (180) days after the closing of the Public Offering.

 

Notwithstanding
the lock up provisions, the undersigned will be able to sell, during any one week in the Lock-Up Period Ordinary Shares and/or Investor
Warrants representing up to an aggregate of the American Depositary Shares of the Company equal to 15% of the average daily trading volume
during the immediately preceding calendar week, as defined by Bloomberg LLP. No shares that may be sold but are not sold may be carried
over from one week to the next. In addition, the lock up provisions of this letter and the 15% weekly leak out provision, will terminate
prior to the end of the Lock-Up Period as follows, (i) as to 50% of the Relevant Securities, if the average daily closing price, as reported
by Bloomberg LLP, at which an American Depositary Shares trades in any consecutive 10 trading days exceeds 200% of the initial IPO offering
price of a American Depositary Share (disregarding any amount attributable to the Investor Warrant) and (ii) as to 100% of the Relevant
Securities, if the average daily closing price, as reported by Bloomberg LLP, at which an American Depositary Share trades in any consecutive
14 trading days exceeds 225% of the initial IPO offering price of a American Depositary Share (disregarding any amount attributable to
the Investor Warrant.

 

In
addition, the undersigned further agrees that, except for the registration statement filed or to be filed in connection with the Public
Offering, during the Lock-Up Period the undersigned will not, without the prior written consent of the Representative: (a) file or participate
in the filing with the SEC of any registration statement or circulate or participate in the circulation of any preliminary or final prospectus
or other disclosure document, in each case with respect to any proposed offering or sale of a Relevant Security beneficially owned by
the undersigned, or (b) exercise any rights the undersigned may have to require registration with the SEC of any proposed offering or
sale of a Relevant Security beneficially owned by the undersigned.

 

In
furtherance of the undersigned’s obligations hereunder, the undersigned hereby authorizes the Company during the Lock-Up Period
to cause any transfer agent for the Relevant Securities to decline to transfer, and to note stop transfer restrictions on the stock register
and other records relating to, Relevant Securities for which the undersigned is the record owner and the transfer of which would be a
violation of this Agreement and, in the case of Relevant Securities for which the undersigned is the beneficial but not the record owner,
agrees that during the Lock-Up Period it will use its reasonable best efforts to cause the record owner to authorize the Company to cause
the relevant transfer agent to decline to transfer, and to note stop transfer restrictions on the stock register and other records relating
to, such Relevant Securities to the extent such transfer would be a violation of this Agreement.

 

    	 

     

    

 

Notwithstanding
the foregoing, the undersigned may transfer the undersigned’s Relevant Securities:

 

	 	(i)	as
    a bona fide gift or gifts;
	 	 	 
	 	(ii)	to
    any trust, partnership, limited liability company or other legal entity commonly used for estate planning purposes which is established
    for the direct or indirect benefit of the undersigned or a member or members of the immediate family of the undersigned;
	 	 	 
	 	(iii)	if
    the undersigned is a corporation, partnership, limited liability company, trust or other business entity, (1) to another corporation,
    partnership, limited liability company, trust or other business entity that is a direct or indirect affiliate (as defined in Rule
    405 under the Securities Act of 1933, as amended) of the undersigned, (2) to limited partners, limited liability company members
    or stockholders of the undersigned or holders of similar equity interests in the undersigned, or (3) in connection with a sale, merger
    or transfer of all or substantially all of the assets of the undersigned or any other change of control of the undersigned, not undertaken
    for the purpose of avoiding the restrictions imposed by this Agreement;
	 	 	 
	 	(iv)	if
    the undersigned is a trust, to the beneficiary of such trust;
	 	 	 
	 	(v)	by
    testate or intestate succession;
	 	 	 
	 	(vi)	by
    operation of law, such as pursuant to a qualified domestic order or in connection with a divorce settlement;
	 	 	 
	 	(vii)	pursuant
    to the Underwriting Agreement; or
	 	 	 
	 	(viii)	to
    the Company, if the Company agrees, solely in an amount necessary to satisfy tax obligations (withholding or otherwise) in connection
    with any grant of restricted Ordinary Shares, exercise or vesting of options or warrants to purchase Ordinary Shares. 

 

provided,
however, in the case of clauses (i)-(vi), that (A) such transfer shall not involve a disposition for value, (B) the transferee agrees
in writing with the Underwriters and the Company to be bound by the terms of this Agreement, and (C) such transfer would not require
any filing under Section 16(a) of the Exchange Act and no such filing is voluntarily made.

 

For
purposes of this Agreement, “immediate family” shall mean any relationship by blood, marriage or adoption, not more remote
than first cousin.

 

The
undersigned hereby represents and warrants that (a) the undersigned has full power and authority to enter into this Agreement, (b) this
Agreement has been duly authorized (if the undersigned is not a natural person) or, in the case of a natural person, such person has
the legal capacity to enter into this Agreement, and (c) this Agreement constitutes the legal, valid and binding obligation of the undersigned,
enforceable against the undersigned in accordance with its terms. Upon request, the undersigned will execute any additional documents
necessary in connection with the enforcement hereof. Any obligations of the undersigned shall be binding upon the successors and assigns
of the undersigned from the date of this Agreement.

 

The
undersigned understands that, if the Underwriting Agreement does not become effective, or if the Underwriting Agreement (other than the
provisions thereof which survive termination) shall terminate or be terminated prior to payment for and delivery of the Securities to
be sold thereunder, the undersigned shall be released from all obligations under this Agreement.

 

The
undersigned, whether or not participating in the Public Offering, understands that the Underwriters are entering into the Underwriting
Agreement and proceeding with the Public Offering in reliance upon this Agreement.

 

    	 

     

    

 

This
Agreement shall be governed by and construed in accordance with the law of the State of New York. Delivery of a signed copy of this Agreement
by facsimile or e-mail/.pdf transmission shall be effective as the delivery of the original hereof.

 

	 	Very truly yours,
	 	 	 
	 	Signature:	 
	 	 	 
	 	Name
    (printed):	 
	 	 	 
	 	Title
    (if applicable):	 
	 	 	 
	 	Entity
    (if applicable):

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00338-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00338-of-00352.parquet"}]]